Positive News SentimentPositive NewsNASDAQ:MGTX MeiraGTx (MGTX) Stock Price, News & Analysis $8.62 +0.22 (+2.57%) As of 10:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About MeiraGTx Stock (NASDAQ:MGTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MeiraGTx alerts:Sign Up Key Stats Today's Range$8.43▼$8.6550-Day Range$7.30▼$8.4052-Week Range$3.97▼$8.98Volume36,858 shsAverage Volume495,504 shsMarket Capitalization$693.16 millionP/E RatioN/ADividend YieldN/APrice Target$24.00Consensus RatingBuy Company Overview MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies. The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders. MeiraGTx has established an end-to-end platform encompassing vector design, process development, and manufacturing scale-up, with capabilities housed in facilities across the United Kingdom and the United States. This integrated approach aims to accelerate the transition from preclinical research to clinical trials and, ultimately, patient access. MeiraGTx completed its initial public offering on the Nasdaq in April 2018 and operates research laboratories in London alongside a manufacturing and clinical operations center in the New York metropolitan area. The company’s leadership team comprises industry veterans with extensive experience in gene therapy development, regulatory affairs and commercialization. MeiraGTx continues to advance its clinical programs in collaboration with academic institutions and contract research organizations, targeting global patient populations in need of novel therapeutic options.AI Generated. May Contain Errors. Read More MeiraGTx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreMGTX MarketRank™: MeiraGTx scored higher than 86% of companies evaluated by MarketBeat, and ranked 147th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingMeiraGTx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialMeiraGTx has a consensus price target of $24.00, representing about 180.1% upside from its current price of $8.57.Amount of Analyst CoverageMeiraGTx has only been the subject of 1 research reports in the past 90 days.Read more about MeiraGTx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MeiraGTx are expected to grow in the coming year, from ($1.48) to $0.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MeiraGTx is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MeiraGTx is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMeiraGTx has a P/B Ratio of 9.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MeiraGTx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.59% of the outstanding shares of MeiraGTx have been sold short.Short Interest Ratio / Days to CoverMeiraGTx has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in MeiraGTx has recently increased by 5.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMeiraGTx does not currently pay a dividend.Dividend GrowthMeiraGTx does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.54 Percentage of Shares Shorted4.59% of the outstanding shares of MeiraGTx have been sold short.Short Interest Ratio / Days to CoverMeiraGTx has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in MeiraGTx has recently increased by 5.43%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News SentimentN/A News SentimentMeiraGTx has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.Search Interest6 people have searched for MGTX on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MeiraGTx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $583,055.00 in company stock.Percentage Held by InsidersOnly 7.50% of the stock of MeiraGTx is held by insiders.Percentage Held by Institutions67.48% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MeiraGTx's insider trading history. Receive MGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MeiraGTx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MGTX Stock News HeadlinesMeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy VitalSeptember 25, 2025 | seekingalpha.comMeiraGTx Holdings PLC Reports Q2 2025 Earnings: EPS of -$0. ...August 16, 2025 | gurufocus.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.October 3 at 2:00 AM | Brownstone Research (Ad)MeiraGTx Reports Progress in Genetic Medicines DevelopmentAugust 15, 2025 | msn.comMeiraGTx reports Q2 EPS (48c) vs (76c) last yearAugust 14, 2025 | msn.comMeiraGTx Reports Second Quarter 2025 Financial and Operational ResultsAugust 14, 2025 | globenewswire.comMeiraGTx Holdings plc's (NASDAQ:MGTX) large institutional owners must be happy as stock continues to impress, up 25% over the past weekJuly 9, 2025 | finance.yahoo.comInsider Sell Alert: Alexandria Forbes Sells 47,500 Shares of MeiraGTx Holdings PLCJuly 8, 2025 | gurufocus.comSee More Headlines MGTX Stock Analysis - Frequently Asked Questions How have MGTX shares performed this year? MeiraGTx's stock was trading at $6.09 on January 1st, 2025. Since then, MGTX shares have increased by 40.7% and is now trading at $8.5690. How were MeiraGTx's earnings last quarter? MeiraGTx Holdings PLC (NASDAQ:MGTX) announced its quarterly earnings data on Thursday, August, 14th. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.04. The firm earned $3.69 million during the quarter, compared to analysts' expectations of $8 million. MeiraGTx had a negative net margin of 415.39% and a negative trailing twelve-month return on equity of 314.44%. When did MeiraGTx IPO? MeiraGTx (MGTX) raised $75 million in an initial public offering (IPO) on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager. How do I buy shares of MeiraGTx? Shares of MGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MeiraGTx own? Based on aggregate information from My MarketBeat watchlists, some other companies that MeiraGTx investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Moderna (MRNA). Company Calendar Last Earnings8/14/2025Today10/03/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MGTX CIK1735438 Webwww.meiragtx.com Phone(646) 860-7985FaxN/AEmployees300Year Founded2015Price Target and Rating Average Price Target for MeiraGTx$24.00 High Price Target$35.00 Low Price Target$13.00 Potential Upside/Downside+185.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$147.79 million Net Margins-415.39% Pretax Margin-415.39% Return on Equity-314.44% Return on Assets-63.28% Debt Debt-to-Equity Ratio26.29 Current Ratio0.88 Quick Ratio0.88 Sales & Book Value Annual Sales$33.28 million Price / Sales20.31 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book9.66Miscellaneous Outstanding Shares80,450,000Free Float74,413,000Market Cap$675.78 million OptionableOptionable Beta1.34 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:MGTX) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredChina’s message to TrumpPorter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MeiraGTx Holdings PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share MeiraGTx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.